Mankind Pharma Limited has scheduled an investor meeting in Singapore for May 25, 2026, and May 26, 2026. The company’s management and officials will meet with various investors in person during these dates. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company clarified that no unpublished price sensitive information (UPSI) shall be disclosed during the meeting. Discussions will be based on the general business outlook and information that is already available in the public domain. The schedule for the Investor Conference remains subject to change due to exigencies on either side.

The intimation regarding participation in the Investor Conference has been uploaded on the official website of Mankind Pharma Limited. The announcement was signed by Hitesh Kumar Jain, Company Secretary & Compliance Officer of Mankind Pharma Limited.

Mankind Pharma Limited has released its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported a revenue from operations of INR 14,278 crore for FY26, an increase of 17.0% year-on-year. For the quarter ended March 31, 2026, revenue stood at INR 3,443 crore, up 11.8% YoY from INR 3,080 crore in the same period last year. In a subsequent concall update, management indicated expectations of double-digit revenue growth from global operations in FY27, alongside adjusted EBITDA margins in the range of 25.5% to 26.5%. Notably, management also clarified that the company is now targeting high-teen growth going forward, rather than the 50-60% growth rates previously referenced. The audio recording of the investor conference call held on May 20, 2026, is available on the company's website.

Consolidated Financial Performance

For the full year FY26, the company reported a Profit After Tax (PAT) of INR 1,938 crore. The adjusted EBITDA for the year was INR 3,629 crore, with a margin of 25.4%. In Q4 FY26, net profit increased to INR 560 crore compared to INR 425 crore in Q4 of the previous year, while adjusted EBITDA rose to INR 930 crore from INR 684 crore YoY. The adjusted EBITDA margin for Q4 expanded to 27% from 22.22% in the prior year period.

The following table summarises the consolidated financial performance:

The Q4 performance is summarised below:

Segmental Performance

Domestic revenue for FY26 grew by 14.4% YoY to INR 12,217 crore, driven by double-digit growth in the Mankind business and strong performance in the BSV specialty portfolio. Consumer Healthcare revenue increased by 8.7% to INR 879 crore. Exports revenue surged by 34.5% YoY to INR 2,061 crore. In Q4, domestic revenue stood at INR 2,886 crore, while exports were INR 557 crore.

Operational Highlights

The company's diluted EPS for FY26 was INR 46.3, a decrease of 5.7% YoY, while Cash EPS increased by 5.6% to INR 68.1. The CFO to EBITDA ratio improved to 89% for FY26 compared to 80% in the previous year. Management noted that domestic business growth was led by cardiac and anti-diabetes therapies, while the OTC business grew by 20% led by e-commerce.

Management Outlook for FY27

Management has shared its outlook for the upcoming financial year, with a key strategic clarification emerging from the concall — the company is now targeting high-teen growth going forward, moving away from the 50-60% growth trajectory previously discussed. The company expects double-digit revenue growth from global operations in FY27. The key guidance parameters are summarised below:

Board Decisions

The Board of Directors, in its meeting held on May 19, 2026, approved the audited financial results. Additionally, the Board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director for a term of five years effective from September 23, 2026, subject to shareholder approval. The Board also approved an additional investment of up to INR 500 crores in Mankind Medicare Private Limited, a wholly owned subsidiary, in one or more tranches. Furthermore, the Board took note of the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, effective from the close of business hours on May 31, 2026.